In a clinical trial on advanced metastatic melanoma, pre-treatment with BRAF and MEK inhibitors was used to decrease glycolytic activity in melanomas with BRAF mutations, leading to normalization of LDH levels in 74% of patients over eight weeks85. This evidence concerns the gene BRAF and melanoma.